(Q22241786)

ORCID Public Data File 2021

7 February 2023

Carlo Patrono

17

Carlo

Patrono

1 reference

7 February 2023

Miguel Sousa Uva

19

Miguel Sousa

Uva

1 reference

7 February 2023

14

Nikolaus

Marx

Nikolaus Marx

1 reference

7 February 2023

18

Petar

Seferovic

Petar Seferovic

1 reference

7 February 2023

15

Linda

Mellbin

Linda Mellbin

1 reference

7 February 2023

Lars Rydén

3

Lars

Rydén

1 reference

7 February 2023

Peter J Grant

4

Peter J

Grant

1 reference

7 February 2023

Christian Berne

6

Christian

Berne

1 reference

7 February 2023

Nicolas Danchin

8

Nicolas

Danchin

1 reference

7 February 2023

Javier Escaned

10

Javier

Escaned

1 reference

7 February 2023

Hans-Peter Hammes

11

Hans-Peter

Hammes

1 reference

7 February 2023

Heikki Huikuri

12

Heikki

Huikuri

1 reference

7 February 2023

Jan Ostergren

16

Jan

Ostergren

1 reference

7 February 2023

Marja-Riita Taskinen

20

Marja-Riita

Taskinen

1 reference

7 February 2023

Paul Valensi

23

Paul

Valensi

1 reference

7 February 2023

Jose Luis Zamorano

24

Jose Luis

Diabetes and Vascular Disease Research

Zamorano

1 reference

7 February 2023

language of work or name

English

0 references

publication date

1 May 2014

0 references

published in

0 references

volume

11

0 references

issue

3

0 references

page(s)

133-173

0 references

cites work

Diagnosis and classification of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Active Smoking and the Risk of Type 2 Diabetes

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators

20 April 2017

1 reference

https://api.crossref.org/works/10.1177/1479164114525548

Effects of intensive glucose lowering in type 2 diabetes

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

10-year follow-up of intensive glucose control in type 2 diabetes

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Glucose control and vascular complications in veterans with type 2 diabetes

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of torcetrapib in patients at high risk for coronary events

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Apixaban versus warfarin in patients with atrial fibrillation

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

20 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Follow-up report on the diagnosis of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Shifting from glucose diagnostic criteria to the new HbA(1c) criteria would have a profound impact on prevalence of diabetes among a high-risk Spanish population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

HbA(1c) in diagnosing and predicting Type 2 diabetes in impaired glucose tolerance: the Finnish Diabetes Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Impact of 3-year lifestyle intervention on postprandial glucose metabolism: the SLIM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The diabetes risk score: a practical tool to predict type 2 diabetes risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Tools for predicting the risk of type 2 diabetes in daily practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Two prospective studies found that elevated 2-hr glucose predicted male mortality independent of fasting glucose and HbA1c

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The impact of gender and general risk factors on the occurrence of atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Do men develop type 2 diabetes at lower body mass indices than women?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The role of physical activity in type 2 diabetes prevention: physiological and practical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

A European evidence-based guideline for the prevention of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study--secondary analysis of the randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Associations between the ankle-brachial index and cardiovascular and all-cause mortality are similar in individuals without and with type 2 diabetes: nineteen-year follow-up of a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: A review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Cardiovascular risk prediction is improved by adding asymptomatic coronary status to routine risk assessment in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Intake of fruit, vegetables, and antioxidants and risk of type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Physical activity consultation for people with Type 2 diabetes: evidence and guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Estimates of global mortality attributable to smoking in 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Are individuals with diabetes seeing better?: a long-term epidemiological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and th

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Long-term effects of intensive glucose lowering on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effect of nateglinide on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Impaired awareness of hypoglycaemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Hypoglycemia and cardiovascular risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Hypoglycaemia and cognitive function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Long-term follow-up after tight control of blood pressure in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Cardiovascular events during differing hypertension therapies in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Renal and retinal effects of enalapril and losartan in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Preventing microalbuminuria in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The safety of statins in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

ESC/EAS Guidelines for the management of dyslipidaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Platelet activation in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Thromboxane biosynthesis and platelet function in type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American Co

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Antiplatelet agents for the treatment and prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISM

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Multimodality imaging in diabetic heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Diabetes, Insulin Resistance, and the Metabolic Syndrome in Patients With Acute Myocardial Infarction Without Previously Known Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Metabolic management of acute myocardial infarction comes to the fore and extends beyond control of hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Implications of Diabetes in Patients With Acute Coronary Syndromes The Global Registry of Acute Coronary Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Guidelines on myocardial revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Diabetic patients and beta-blockers after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of beta-blockers on glucose and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: a contemporary meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

A randomized trial of therapies for type 2 diabetes and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute cor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Comparative effectiveness of revascularization strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Strategies for multivessel revascularization in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Outcome of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (a SORT OUT III Substudy)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Early versus delayed, provisional eptifibatide in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Facilitated PCI in patients with ST-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Bilateral internal thoracic artery harvest and deep sternal wound infection in diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Superiority of moderate control of hyperglycemia to tight control in patients undergoing coronary artery bypass grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Impact of diabetes mellitus on the treatment effect of percutaneous or surgical revascularization for patients with unprotected left main coronary artery disease: a subgroup analysis of the MAIN-COMPARE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The association between glucose abnormalities and heart failure in the population-based Reykjavik study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The Framingham Study, diabetes mellitus and cardiovascular disease: turning back the clock

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Diabetes, left ventricular systolic dysfunction, and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Increasing glucose levels and BMI predict future heart failure experience from the Reykjavík Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Recommendations for the evaluation of left ventricular diastolic function by echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effect of valsartan on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effect of carvedilol on survival in severe chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

CHART: congestive cardiac failure in hospitals, an Australian review of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

2010 Focused Update of ESC Guidelines on device therapy in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

What predicts long-term survival after heart transplantation? An analysis of 9,400 ten-year survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Metformin use and mortality in ambulatory patients with diabetes and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Incidence of and risk factors for atrial fibrillation in older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Independent predictors of stroke in patients with atrial fibrillation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effect of clopidogrel added to aspirin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Sudden death due to cardiac arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Task Force on Sudden Cardiac Death of the European Society of Cardiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Sudden coronary death in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Prospective study of sudden cardiac death among women in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiolo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Diabetes, glucose level, and risk of sudden cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Reflex and tonic autonomic markers for risk stratification in patients with type 2 diabetes surviving acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Apixaban in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Peripheral arterial disease--epidemiological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Prevalence of and risk factors associated with carotid artery stenosis: the Tromsø Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Smoking Cessation Strategies in Patients with Peripheral Arterial Disease: An Evidence-based Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Development of life-expectancy tables for people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Major coronary risk factors and death from coronary heart disease: baseline and follow-up mortality data from the Second National Health and Nutrition Examination Survey (NHANES II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The prognostic value of impaired walking distance on long-term outcome in patients with known or suspected peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Home versus center based physical activity programs in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

21 January 2018

Chapter V: Diabetic foot

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Diabetes and cardiovascular disease. The Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

What strategies are effective for exercise adherence in heart failure? A systematic review of controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Fixed-dose combinations improve medication compliance: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Patient adherence to medical treatment: a review of reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Randomized trials of nursing interventions for secondary prevention in patients with coronary artery disease and heart failure: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Prognosis of patients with atherothrombotic disease: A prospective survey in a non-hospital setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial†

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Bypass Versus Drug-Eluting Stents at Three Years in SYNTAX Patients With Diabetes Mellitus or Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Diabetic and Nondiabetic Patients With Left Main and/or 3-Vessel Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Primary Percutaneous Coronary Intervention Compared With Fibrinolysis for Myocardial Infarction in Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Haemoglobin A1c levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Left atrial velocity vector imaging for the detection and quantification of left ventricular diastolic function in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Balancing the benefits of statins versus a new risk-diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Long-term results following operation for diabetic foot problems: arterial disease confers a poor prognosis

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Spironolactone in patients with heart failure

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Cardiovascular determinants of carotid artery disease. The Rotterdam Elderly Study

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Exercise Training for Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in ID

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Heart Failure Prevalence, Incidence, and Mortality in the Elderly With Diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164114525548

7 January 2021

Identifiers

DOI

10.1177/1479164114525548

1 reference

Consolidated OpenCitations Corpus – April 2017

404406

404406

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference